Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 80Unknown 22Terminated 13Active not recruiting 12Recruiting 11Withdrawn 4

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Sarcoma 2

Conditions

Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Hodgkin Disease 1

Interventions

Rituximab 55Cyclophosphamide 45Vincristine 23fludarabine phosphate 21Cytarabine 20fludarabine 19Etoposide 19Prednisone 18Bendamustine Hydrochloride 18ibrutinib 17Methotrexate 17Doxorubicin 17Lenalidomide 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 12venetoclax 11Melphalan 11Dexamethasone 11Whole-Body Irradiation 8Tacrolimus 8Busulfan 8Brentuximab Vedotin 8Biopsy 8pembrolizumab 7duvelisib 7Nivolumab 7Mycophenolic Acid 7Gemcitabine 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Ifosfamide × Lymphoid × Clear all
NCT03349346 2018-12-11

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Gilead Sciences

Phase 1 Withdrawn
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Western Regional Medical Center

Phase 1/2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00829205 2013-08-26

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00801918 2013-05-15

Denileukine Diftitox for Relapsed ALCL

Columbia University

Phase 2 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡